BI 54903

Drug Profile

BI 54903

Alternative Names: BI54903

Latest Information Update: 10 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 10 Oct 2014 No development reported - Phase-I for Asthma (In volunteers) in Germany (Inhalation)
  • 10 Oct 2014 No development reported - Phase-II for Asthma in USA (Inhalation)
  • 16 Nov 2011 Boehringer Ingelheim terminates three phase II trial in Asthma in USA (NCT01397162, NCT01397201, NCT01396278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top